# A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B

> **NCT02332473** · PHASE2 · COMPLETED · sponsor: **Xiamen Amoytop Biotech Co., Ltd.** · enrollment: 110 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Ypeginterferon alfa-2b
- **DRUG:** Granulocyte-macrophage colony stimulating factor

## Key facts

- **NCT ID:** NCT02332473
- **Lead sponsor:** Xiamen Amoytop Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2016-02
- **Final completion:** 2016-08
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2017-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02332473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02332473, "A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02332473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*